Company / Operating Income
Protalix BioTherapeutics, Inc. Operating Income History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$10.5M
FY2025
5-year range
-$20.5M / $10.5M
FY2021-FY2025
Trend
+180.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$35M in FY2019 to $10M in FY2025.
Based on SEC 10-K filings.
$10M in FY2025 with a 3-year CAGR of +56.9%.
Improved from -$20M to $10M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- +56.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +56.9%, indicating consistent growth.
- In FY2025, operating income increased 180.4% year-over-year.
- Lowest operating income in the period was in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.5M | +180.4% |
| FY2024 | -$13.0M | +36.4% |
| FY2023 | -$20.5M | -855.1% |
| FY2022 | $2.7M | +125.3% |
| FY2021 | -$10.7M | +44.5% |
| FY2020 | -$19.3M | +44.1% |
| FY2019 | -$34.5M | -45.8% |
| FY2017 | -$23.7M | +17.1% |
| FY2016 | -$28.6M | +16.2% |
| FY2015 | -$34.1M | -179.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026